Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;42(3):531-51.
doi: 10.1016/j.rdc.2016.03.010.

New Treatment Guidelines for Sjögren's Disease

Affiliations
Review

New Treatment Guidelines for Sjögren's Disease

Frederick B Vivino et al. Rheum Dis Clin North Am. 2016 Aug.

Abstract

Sjögren's disease is associated with a high burden of illness, diminished quality of life, and increased health care costs. The Sjögren's Syndrome Foundation developed the first US clinical practice guidelines for management of the oral, ocular, and rheumatologic or systemic manifestations. Guideline recommendations were reviewed by a consensus expert panel using a modified Delphi process. This initiative should improve the quality and consistency of care for Sjögren's disease in the United States, guide insurance reimbursement, and define areas for future study. Guidelines will be periodically reviewed and revised as new information becomes available.

Keywords: Arthritis; Biologics; Caries; DMARDS; Dry eye; Fatigue; Sjögren's; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Biogen (F.B. Vivino, S.E. Carson). Coda, Inc; Kala, Inc; Lexitas, Inc; Parion, Inc; Shire Pharmaceuticals, Inc; TearLab, Inc (G. Foulks). None (T.E. Daniels, K.M. Hammitt). UCB; Biogen (A. Parke). Daiichi Sankyo (M.T. Brennan). Alcon; Allergan; Bausch & Lomb; Eleven Biotherapeutics; Nicox; TearScience (S.L. Forstot). UCB (R.H. Scofield).

Figures

Fig. 1
Fig. 1
The SSF clinical practice guidelines process.
Fig. 2
Fig. 2
(A) Review of fluoride use for caries prevention in SD. (B) Review of salivary stimulation for caries prevention in SD. OTC, over-the-counter. (C) Review of antimicrobials for caries prevention in SD. (D) Review of nonfluoride remineralizing agents for caries prevention in SD.
Fig. 2
Fig. 2
(A) Review of fluoride use for caries prevention in SD. (B) Review of salivary stimulation for caries prevention in SD. OTC, over-the-counter. (C) Review of antimicrobials for caries prevention in SD. (D) Review of nonfluoride remineralizing agents for caries prevention in SD.
Fig. 3
Fig. 3
Review of treatments for dry eye. a Best evidence.
Fig. 4
Fig. 4
(A) Review of disease-modifying antirheumatic drug (DMARD) use for musculoskeletal pain in SD. (B) Review of treatments for fatigue in SD. (C) Review of biological medication use in SD.

Similar articles

Cited by

References

    1. Valtýsdóttir ST, Gudbjörnsson B, Lindqvist U, et al. Anxiety and depression in patients with primary Sjögren’s syndrome. J Rheumatol. 2000;27(1):165–9. - PubMed
    1. Vitali C, Tavoni A, Neri R, et al. Fibromyalgia Features in Patients with Primary Sjögren’s Syndrome: Evidence of a Relationship with Psychological Depression. Scand J Rheumatol. 1989;18(1):21–7. - PubMed
    1. Mishra R, Vivino FB. Diagnosis and management of fatigue. In: Wallace DJ, editor. The Sjögren’s book. New York: The Sjögren’s Syndrome Foundation and Oxford University Press; 2012. pp. 228–34.
    1. Segal B, Bowman SJ, Fox PC, et al. Primary Sjögren’s Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009;7:46. - PMC - PubMed
    1. Strömbeck B, Ekdahl C, Manthorpe R, et al. Health-related quality of life in primary Sjögren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol. 2000;29(1):20–281. - PubMed

MeSH terms